Searched for
NIASPAN
Brokerages bullish on Lupin post Q2 results; raise target priceThe company reported a 55 per cent jump in net profit at Rs 630 crore. It had reported a net profit of Rs 406 crore in the corresponding qu...- Sun shines in pharma space; M-cap greater than DRL, Lupin, Cipla & Ranbaxy combinedThe market capitalisation of Sun Pharmaceuticals exceeded that of Dr Reddy's, Lupin, Cipal and Ranbaxy Laboratories combined on Wednesday, ...
- Sensex turns choppy in special trading session; top ten stocks in focusSensex turned choppy in a listless special trade on Saturday in absence of any major global cues. The index was weighed down by losses in m...
- Ten stocks in focus in Saturday morning trade"The Nifty has been forming higher tops and higher bottoms; it has also closed above the previous swing’s high which is a positive sign," S...
- Lupin launches generic Niaspan tablets in US marketThe company's US subsidiary, Lupin Pharmaceuticals Inc has launched the generic Niaspan tablets in multiple strengths of 500mg, 750 mg & 10...
- Have about 200 drug filings in US, 100 have got approvals: Ramesh Swaminathan, Lupin'We do expect nicotinic acid and Aspen to be launched by the end of this quarter,' says Ramesh Swaminathan.
- Analysts see over 20% upside in Cadila Healthcare after strong Q3 showGiven the overall technical picture, there is a strong possibility of a price breakout occurring at the end of February 2014.
- Brokerages up target price on Lupin to over Rs 1,000 post Q2 resultsAs many as seven brokerage firms have a target price of over Rs 1,000, which translates into gains of over 10 per cent in the next one year.
- Lupin remains top pick of brokerages in pharma spaceThe stock has extended overnight gains after the company reported a Q4 net profit of Rs 408 crore, up 161 pc YoY.
- Pfizer halts cholesterol drug trial, shares may take a hitPfizer’s shares will likely plunge after the world’s biggest drugmaker unexpectedly ended development of its most important new drug, a cho...
Load More
